About us

YUMAB develops fully human antibodies from target to lead for clients and partners worldwide.

Its proprietary antibody platform covers all technologies from antibody discovery – using one of the world’s largest, natural human antibody library collection (>10e11) or customized, patient-derived or immune libraries – to antibody engineering and lead optimization.

YUMAB antibodies contain natural, close to germ-line sequences promising low immunogenicity and toxicity. The advanced in vitro and on-cell selection technologies pre-design antibody properties, such as interspecies X-reactivity and developability, early in the development process and provide high success-rates to all types of antigens, including difficult targets like GPCRs or ion channels.

Bioinformatic optimization and in vitro evolution technologies provide a direct path towards optimized lead candidates for all antibody drug formats such as full-length IgG, Fab, scFv, bispecifics, CARs, fusion proteins and ADCs.

Products and services

  • Discovery of Novel Fully Human Antibodies

  • Antibody Lead Development & Optimization until Final Sequence

  • Antibody Engineering – e.g. Affinity, Stability, Manufacturability

  • Humanization

  • Antibody Libraries

  • Antibody Analytics & Bioassays

Inhoffenstr. 7
38124 Brunswick

Phone: +49 531 4811700
Internet: www.yumab.com
E-mail: Send message

Contact person

Dr. Linda Kirchner
Administration & Finances
Phone: +49 531 4811700
E-mail: Send message

Click here if you notice an image that violates copyright or privacy rights.

Get in contact

We use cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection